Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Breast Cancer

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 177 articles: HTML format

Single Articles

May 2024
1. SHEN F, Jiang G, Philips S, Cantor E, et al
   Germline predictors for bevacizumab induced hypertensive crisis in ECOG-ACRIN 5103 and BEATRICE.
   Br J Cancer. 2024;130:1348-1355.
   PubMed     Abstract available
   
   
   April 2024
2. CHANG CY, Jones BL, Hincapie-Castillo JM, Park H, et al
   Association between trajectories of adherence to endocrine therapy and risk of treated breast cancer recurrence among US nonmetastatic breast cancer survivors.
   Br J Cancer. 2024 Apr 18. doi: 10.1038/s41416-024-02680.
   PubMed     Abstract available
   
   
   
3. BRAUN M, Piasecka D, Sadej R, Romanska HM, et al
   FGFR4-driven plasticity in breast cancer progression and resistance to therapy.
   Br J Cancer. 2024 Apr 17. doi: 10.1038/s41416-024-02658.
   PubMed     Abstract available
   
   
   
4. ARSHAD M, Azad A, Chan PYK, Vigneswara V, et al
   Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models.
   Br J Cancer. 2024 Apr 10. doi: 10.1038/s41416-024-02665.
   PubMed     Abstract available
   
   
   
5. ALEXANDER J, Schipper K, Nash S, Brough R, et al
   Pathway-based signatures predict patient outcome, chemotherapy benefit and synthetic lethal dependencies in invasive lobular breast cancer.
   Br J Cancer. 2024 Apr 10. doi: 10.1038/s41416-024-02679.
   PubMed     Abstract available
   
   
   March 2024
6. LIU X, Cheng X, Xie F, Li K, et al
   Persistence of peripheral CD8 + CD28- T cells indicates a favourable outcome and tumour immunity in first-line HER2-positive metastatic breast cancer.
   Br J Cancer. 2024 Mar 22. doi: 10.1038/s41416-024-02610.
   PubMed     Abstract available
   
   
   
7. TEN VELDE DE, Duijm LEM, van der Sangen MJC, Schipper RJ, et al
   Long-term trends in incidence, characteristics and prognosis of screen-detected and interval cancers in women participating in the Dutch breast cancer screening programme.
   Br J Cancer. 2024 Mar 11. doi: 10.1038/s41416-024-02633.
   PubMed     Abstract available
   
   
   February 2024
8. YU T, Yang C, Li M
   Comment on "Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases".
   Br J Cancer. 2024 Feb 20. doi: 10.1038/s41416-024-02616.
   PubMed    
   
   
   
9. SONG X, Fang C, Dai Y, Sun Y, et al
   Cyclin-dependent kinase 7 (CDK7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer.
   Br J Cancer. 2024 Feb 14. doi: 10.1038/s41416-024-02589.
   PubMed     Abstract available
   
   
   
10. YE HS, Zhou D, Li H, Lv J, et al
    Organoid forming potential as complementary parameter for accurate evaluation of breast cancer neoadjuvant therapeutic efficacy.
    Br J Cancer. 2024 Feb 10. doi: 10.1038/s41416-024-02595.
    PubMed     Abstract available
    
    
    
11. AXELSEN TV, Olesen C, Khan D, Mohammadi A, et al
    Antibodies toward Na(+),HCO(3)(-)-cotransporter NBCn1/SLC4A7 block net acid extrusion and cause pH-dependent growth inhibition and apoptosis in breast cancer.
    Br J Cancer. 2024 Feb 3. doi: 10.1038/s41416-024-02591.
    PubMed     Abstract available
    
    
    
12. HOLT S, Verrill M, Pettit L, Rigg A, et al
    A UK prospective multicentre decision impact, decision conflict and economic evaluation of the 21-gene assay in women with node+ve, hormone receptor+ve, HER2-ve breast cancer.
    Br J Cancer. 2024 Feb 2. doi: 10.1038/s41416-024-02588.
    PubMed     Abstract available
    
    
    
13. MATHIEU E, Noguchi N, Li T, Barratt AL, et al
    Health benefits and harms of mammography screening in older women (75+ years)-a systematic review.
    Br J Cancer. 2024;130:275-296.
    PubMed     Abstract available
    
    
    January 2024
14. GAILLARD T, Piketty J, Feron JG, Girard N, et al
    Rethinking surgical revisions: impact of the MonarchE trial on axillary dissection in hormone-positive HER2-negative early breast cancer patients potentially eligible for abemaciclib.
    Br J Cancer. 2024 Jan 27. doi: 10.1038/s41416-024-02580.
    PubMed     Abstract available
    
    
    
15. SALDAJENO DP, Kawaoka S, Masuda N, Tanaka S, et al
    Time-series blood cytokine profiles correlate with treatment responses in triple-negative breast cancer patients.
    Br J Cancer. 2024 Jan 18. doi: 10.1038/s41416-023-02527.
    PubMed     Abstract available
    
    
    
16. REN Z, Dharmaratne M, Liang H, Benard O, et al
    Redox signalling regulates breast cancer metastasis via phenotypic and metabolic reprogramming due to p63 activation by HIF1alpha.
    Br J Cancer. 2024 Jan 18. doi: 10.1038/s41416-023-02522.
    PubMed     Abstract available
    
    
    
17. VANACKER H, Treilleux I, Schiffler C, Bieche I, et al
    p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane.
    Br J Cancer. 2024 Jan 5. doi: 10.1038/s41416-023-02549.
    PubMed     Abstract available
    
    
    
18. WATTS EL, Gonzales TI, Strain T, Saint-Maurice PF, et al
    Observational and genetic associations between cardiorespiratory fitness and cancer: a UK Biobank and international consortia study.
    Br J Cancer. 2024;130:114-124.
    PubMed     Abstract available
    
    
    
19. TSURUDA KM, Hoff SR, Akslen LA, Hofvind S, et al
    Fatal and non-fatal breast cancers in women targeted by BreastScreen Norway: a cohort study.
    Br J Cancer. 2024;130:99-107.
    PubMed     Abstract available
    
    
    December 2023
20. GRASSMANN F, Malarstig A, Dahl L, Bendes A, et al
    The impact of circulating protein levels identified by affinity proteomics on short-term, overall breast cancer risk.
    Br J Cancer. 2023 Dec 22. doi: 10.1038/s41416-023-02541.
    PubMed     Abstract available
    
    
    
21. LYU L, Li H, Lu K, Jiang S, et al
    PAK inhibitor FRAX486 decreases the metastatic potential of triple-negative breast cancer cells by blocking autophagy.
    Br J Cancer. 2023 Dec 18. doi: 10.1038/s41416-023-02523.
    PubMed     Abstract available
    
    
    
22. LICATA L, Barreca M, Galbardi B, Dugo M, et al
    Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy.
    Br J Cancer. 2023;129:2025-2033.
    PubMed     Abstract available
    
    
    November 2023
23. METCALFE K, Huzarski T, Gronwald J, Kotsopoulos J, et al
    Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis.
    Br J Cancer. 2023 Nov 29. doi: 10.1038/s41416-023-02503.
    PubMed     Abstract available
    
    
    
24. PATEL SA, Hassan MK, Naik M, Mohapatra N, et al
    EEF1A2 promotes HIF1A mediated breast cancer angiogenesis in normoxia and participates in a positive feedback loop with HIF1A in hypoxia.
    Br J Cancer. 2023 Nov 27. doi: 10.1038/s41416-023-02509.
    PubMed     Abstract available
    
    
    
25. CUNHA MT, Gouveia MC, Neto FL, Testa L, et al
    Long-term outcomes of neoadjuvant immunotherapy plus chemotherapy in patients with early-stage triple-negative breast cancer: an extracted individual patient data and trial-level meta-analysis.
    Br J Cancer. 2023 Nov 27. doi: 10.1038/s41416-023-02501.
    PubMed     Abstract available
    
    
    
26. AHMAD AS, Offman J, Delon C, North BV, et al
    Years of life lost due to cancer in the United Kingdom from 1988 to 2017.
    Br J Cancer. 2023;129:1558-1568.
    PubMed     Abstract available
    
    
    October 2023
27. HILL H, Kearns B, Pashayan N, Roadevin C, et al
    The cost-effectiveness of risk-stratified breast cancer screening in the UK.
    Br J Cancer. 2023 Oct 17. doi: 10.1038/s41416-023-02461.
    PubMed     Abstract available
    
    
    
28. KAJIHARA N, Ge Y, Seino KI
    Blocking of oestrogen signals improves anti-tumour effect regardless of oestrogen receptor alpha expression in cancer cells.
    Br J Cancer. 2023;129:935-946.
    PubMed     Abstract available
    
    
    September 2023
29. MAKHLOUF S, Wahab N, Toss M, Ibrahim A, et al
    Evaluation of tumour infiltrating lymphocytes in luminal breast cancer using artificial intelligence.
    Br J Cancer. 2023 Sep 30. doi: 10.1038/s41416-023-02451.
    PubMed     Abstract available
    
    
    
30. GANNON MR, Dodwell D, Aggarwal A, Park MH, et al
    Evidence into practice: a national cohort study of NICE-recommended oncological drug therapy utilisation among women diagnosed with invasive breast cancer in England.
    Br J Cancer. 2023 Sep 23. doi: 10.1038/s41416-023-02439.
    PubMed     Abstract available
    
    
    
31. ATALLAH NM, Alsaleem M, Toss MS, Mongan NP, et al
    Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level.
    Br J Cancer. 2023 Sep 22. doi: 10.1038/s41416-023-02426.
    PubMed     Abstract available
    
    
    
32. ZHANG Y, Zhao G, Yu L, Wang X, et al
    Heat-shock protein 90alpha protects NME1 against degradation and suppresses metastasis of breast cancer.
    Br J Cancer. 2023 Sep 20. doi: 10.1038/s41416-023-02435.
    PubMed     Abstract available
    
    
    
33. MEI J, Cai Y, Chen L, Wu Y, et al
    The heterogeneity of tumour immune microenvironment revealing the CRABP2/CD69 signature discriminates distinct clinical outcomes in breast cancer.
    Br J Cancer. 2023 Sep 15. doi: 10.1038/s41416-023-02432.
    PubMed     Abstract available
    
    
    
34. GIUDICI F, Pistilli B, Vaz-Luis I, Karimi M, et al
    Insights adjusting for non-adherence in randomized clinical trials: a reanalysis of an adjuvant trial of tamoxifen duration in early breast cancer.
    Br J Cancer. 2023 Sep 11. doi: 10.1038/s41416-023-02420.
    PubMed     Abstract available
    
    
    
35. FRIEDLANDER M, Mileshkin L, Lombard J, Frentzas S, et al
    Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial.
    Br J Cancer. 2023;129:797-810.
    PubMed     Abstract available
    
    
    August 2023
36. ZHU S, Lu Y, Fei X, Shen K, et al
    Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases.
    Br J Cancer. 2023 Aug 21. doi: 10.1038/s41416-023-02403.
    PubMed     Abstract available
    
    
    
37. DOU Y, Chen B, Yu X, Xin Q, et al
    Dose response relationship between breast cancer and somatotypes during childhood: a systematic review and meta-analysis.
    Br J Cancer. 2023 Aug 7. doi: 10.1038/s41416-023-02376.
    PubMed     Abstract available
    
    
    
38. MCCARTHY RL, Copson E, Tapper W, Bolton H, et al
    Risk-reducing surgery for individuals with cancer-predisposing germline pathogenic variants and no personal cancer history: a review of current UK guidelines.
    Br J Cancer. 2023;129:383-392.
    PubMed     Abstract available
    
    
    July 2023
39. GAYNOR N, Blanco A, Madden SF, Moran B, et al
    Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy.
    Br J Cancer. 2023 Jul 28. doi: 10.1038/s41416-023-02375.
    PubMed     Abstract available
    
    
    
40. LIEFAARD MC, Moore KS, Mulder L, van den Broek D, et al
    Correction To: Tumour-educated platelets for breast cancer detection: biological and technical insights.
    Br J Cancer. 2023 Jul 24. doi: 10.1038/s41416-023-02371.
    PubMed    
    
    
    
41. PALMIERI C, Musson A, Harper-Wynne C, Wheatley D, et al
    A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance(R) Patient Program.
    Br J Cancer. 2023 Jul 19. doi: 10.1038/s41416-023-02352.
    PubMed     Abstract available
    
    
    
42. PUPPO M, Valluru MK, Croset M, Ceresa D, et al
    MiR-662 is associated with metastatic relapse in early-stage breast cancer and promotes metastasis by stimulating cancer cell stemness.
    Br J Cancer. 2023 Jul 13. doi: 10.1038/s41416-023-02340.
    PubMed     Abstract available
    
    
    
43. XIONG F, Wang J, Nierenberg JL, Van Blarigan EL, et al
    Diabetes mellitus and risk of breast cancer: a large-scale, prospective, population-based study.
    Br J Cancer. 2023 Jul 5. doi: 10.1038/s41416-023-02345.
    PubMed     Abstract available
    
    
    
44. HAMMARSTROM M, Gabrielson M, Crippa A, Discacciati A, et al
    Side effects of low-dose tamoxifen: results from a six-armed randomised controlled trial in healthy women.
    Br J Cancer. 2023;129:61-71.
    PubMed     Abstract available
    
    
    
45. BERGERON A, Bertaut A, Beltjens F, Charon-Barra C, et al
    Anticipating changes in the HER2 status of breast tumours with disease progression-towards better treatment decisions in the new era of HER2-low breast cancers.
    Br J Cancer. 2023;129:122-134.
    PubMed     Abstract available
    
    
    
46. MAK JKL, McMurran CE, Kuja-Halkola R, Hall P, et al
    Clinical biomarker-based biological aging and risk of cancer in the UK Biobank.
    Br J Cancer. 2023;129:94-103.
    PubMed     Abstract available
    
    
    June 2023
47. VIDAL CM, Ouyang C, Qi Y, Mendez-Dorantes C, et al
    Arginine regulates HSPA5/BiP translation through ribosome pausing in triple-negative breast cancer cells.
    Br J Cancer. 2023 Jun 29. doi: 10.1038/s41416-023-02322.
    PubMed     Abstract available
    
    
    
48. DECKER NS, Johnson T, Behrens S, Obi N, et al
    Endogenous estrogen receptor modulating oxysterols and breast cancer prognosis: Results from the MARIE patient cohort.
    Br J Cancer. 2023 Jun 24. doi: 10.1038/s41416-023-02315.
    PubMed     Abstract available
    
    
    
49. ROMANOS-NANCLARES A, Guasch-Ferre M, Willett WC, Chen WY, et al
    Consumption of olive oil and risk of breast cancer in U.S. women: results from the Nurses' Health Studies.
    Br J Cancer. 2023 Jun 13. doi: 10.1038/s41416-023-02306.
    PubMed     Abstract available
    
    
    May 2023
50. MCWILLIAMS L, Ruane H, Ulph F, Woof VG, et al
    What do women think about having received their breast cancer risk as part of a risk-stratified NHS Breast Screening Programme? A qualitative study.
    Br J Cancer. 2023 May 24:1-10. doi: 10.1038/s41416-023-02268.
    PubMed     Abstract available
    
    
    
51. LLOYD R, Pirikahu S, Walter J, Cadby G, et al
    Alternative methods to measure breast density in younger women.
    Br J Cancer. 2023;128:1701-1709.
    PubMed     Abstract available
    
    
    
52. FRANKEN A, Kraemer A, Sicking A, Watolla M, et al
    Comparative analysis of EpCAM high-expressing and low-expressing circulating tumour cells with regard to their clonal relationship and clinical value.
    Br J Cancer. 2023;128:1742-1752.
    PubMed     Abstract available
    
    
    April 2023
53. GARETH EVANS D, McWilliams L, Astley S, Brentnall AR, et al
    Correction To: Quantifying the effects of risk-stratified breast cancer screening when delivered in real time as routine practice versus usual screening: the BC-Predict non-randomised controlled study (NCT04359420).
    Br J Cancer. 2023 Apr 24. doi: 10.1038/s41416-023-02273.
    PubMed    
    
    
    
54. KETCHEMEN JP, Babeker H, Tikum AF, Nambisan AK, et al
    Biparatopic anti-HER2 drug radioconjugates as breast cancer theranostics.
    Br J Cancer. 2023 Apr 24. doi: 10.1038/s41416-023-02272.
    PubMed     Abstract available
    
    
    
55. O'MAHONY DG, Ramus SJ, Southey MC, Meagher NS, et al
    Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2.
    Br J Cancer. 2023 Apr 19. doi: 10.1038/s41416-023-02263.
    PubMed     Abstract available
    
    
    
56. GIRITHAR HN, Staats Pires A, Ahn SB, Guillemin GJ, et al
    Involvement of the kynurenine pathway in breast cancer: updates on clinical research and trials.
    Br J Cancer. 2023 Apr 11. doi: 10.1038/s41416-023-02245.
    PubMed     Abstract available
    
    
    
57. FRENEL JS, Lusque A, Delaloge S, Ferrero JM, et al
    Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation.
    Br J Cancer. 2023 Apr 3. doi: 10.1038/s41416-023-02248.
    PubMed     Abstract available
    
    
    
58. NASRAZADANI A, Li Y, Fang Y, Shah O, et al
    Mixed invasive ductal lobular carcinoma is clinically and pathologically more similar to invasive lobular than ductal carcinoma.
    Br J Cancer. 2023;128:1030-1039.
    PubMed     Abstract available
    
    
    
59. GARETH EVANS D, McWilliams L, Astley S, Brentnall AR, et al
    Quantifying the effects of risk-stratified breast cancer screening when delivered in real time as routine practice versus usual screening: the BC-Predict non-randomised controlled study (NCT04359420).
    Br J Cancer. 2023 Apr 1:1-9. doi: 10.1038/s41416-023-02250.
    PubMed     Abstract available
    
    
    
60. LOH J, Wu J, Chieng J, Chan A, et al
    Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials.
    Br J Cancer. 2023;128:1514-1520.
    PubMed     Abstract available
    
    
    
61. FRENCH DP, McWilliams L, Bowers S, Woof VG, et al
    Psychological impact of risk-stratified screening as part of the NHS Breast Screening Programme: multi-site non-randomised comparison of BC-Predict versus usual screening (NCT04359420).
    Br J Cancer. 2023;128:1548-1558.
    PubMed     Abstract available
    
    
    March 2023
62. SUN GY, Zhang J, Wang BZ, Jing H, et al
    The prognostic value of tumour-infiltrating lymphocytes, programmed cell death protein-1 and programmed cell death ligand-1 in Stage I-III triple-negative breast cancer.
    Br J Cancer. 2023 Mar 25. doi: 10.1038/s41416-023-02218.
    PubMed     Abstract available
    
    
    
63. BENIEY M, Hubert A, Haque T, Cotte AK, et al
    Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer.
    Br J Cancer. 2023 Mar 20. doi: 10.1038/s41416-023-02226.
    PubMed     Abstract available
    
    
    
64. KUMEGAWA K, Saeki S, Takahashi Y, Yang L, et al
    Correction: Chromatin profile-based identification of a novel ER-positive breast cancer subgroup with reduced ER-responsive element accessibility.
    Br J Cancer. 2023 Mar 13. doi: 10.1038/s41416-023-02206.
    PubMed    
    
    
    
65. GUO J, Hu J, Zheng Y, Zhao S, et al
    Artificial intelligence: opportunities and challenges in the clinical applications of triple-negative breast cancer.
    Br J Cancer. 2023 Mar 4. doi: 10.1038/s41416-023-02215.
    PubMed     Abstract available
    
    
    
66. CANAS-MARQUES R, Schnitt SJ
    Ductal carcinoma in situ with and without microinvasion: is there a clinically meaningful difference in outcome?
    Br J Cancer. 2023;128:713-714.
    PubMed    
    
    
    
67. MAO N, Zhang H, Dai Y, Li Q, et al
    Attention-based deep learning for breast lesions classification on contrast enhanced spectral mammography: a multicentre study.
    Br J Cancer. 2023;128:793-804.
    PubMed     Abstract available
    
    
    February 2023
68. HARVIE M, French DP, Pegington M, Lombardelli C, et al
    Randomised controlled trial of breast cancer and multiple disease prevention weight loss programmes vs written advice amongst women attending a breast cancer family history clinic.
    Br J Cancer. 2023 Feb 25:1-11. doi: 10.1038/s41416-023-02207.
    PubMed     Abstract available
    
    
    
69. ZHANG X, Jiang Q, Su Y, Bu L, et al
    AMPK phosphorylates and stabilises copper transporter 1 to synergise metformin and copper chelator for breast cancer therapy.
    Br J Cancer. 2023 Feb 17. doi: 10.1038/s41416-022-02127.
    PubMed     Abstract available
    
    
    
70. LIEFAARD MC, Moore KS, Mulder L, van den Broek D, et al
    Tumour-educated platelets for breast cancer detection: biological and technical insights.
    Br J Cancer. 2023 Feb 10. doi: 10.1038/s41416-023-02174.
    PubMed     Abstract available
    
    
    
71. LUO J, Zou H, Guo Y, Tong T, et al
    The oncogenic roles and clinical implications of YAP/TAZ in breast cancer.
    Br J Cancer. 2023 Feb 9. doi: 10.1038/s41416-023-02182.
    PubMed     Abstract available
    
    
    
72. USHER-SMITH JA, Hindmarch S, French DP, Tischkowitz M, et al
    Proactive breast cancer risk assessment in primary care: a review based on the principles of screening.
    Br J Cancer. 2023 Feb 3:1-11. doi: 10.1038/s41416-023-02145.
    PubMed     Abstract available
    
    
    
73. CASTRO-ESPIN C, Bonet C, Crous-Bou M, Katzke V, et al
    Dietary patterns related to biological mechanisms and survival after breast cancer diagnosis: results from a cohort study.
    Br J Cancer. 2023 Feb 3. doi: 10.1038/s41416-023-02169.
    PubMed     Abstract available
    
    
    
74. KUMEGAWA K, Saeki S, Takahashi Y, Yang L, et al
    Chromatin profile-based identification of a novel ER-positive breast cancer subgroup with reduced ER-responsive element accessibility.
    Br J Cancer. 2023 Feb 1. doi: 10.1038/s41416-023-02178.
    PubMed     Abstract available
    
    
    
75. HOWELL A, Howell SJ
    Tamoxifen evolution.
    Br J Cancer. 2023;128:421-425.
    PubMed    
    
    
    
76. YUN J, Heo W, Lee ES, Na D, et al
    An integrative approach for exploring the nature of fibroepithelial neoplasms.
    Br J Cancer. 2023;128:626-637.
    PubMed     Abstract available
    
    
    January 2023
77. WU HL, Luo ZY, He ZL, Gong Y, et al
    Correction to: All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits.
    Br J Cancer. 2023 Jan 30. doi: 10.1038/s41416-023-02159.
    PubMed    
    
    
    
78. BOTTOSSO M, Griguolo G, Sinoquet L, Guarascio MC, et al
    Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases.
    Br J Cancer. 2023 Jan 30. doi: 10.1038/s41416-023-02153.
    PubMed     Abstract available
    
    
    
79. CURIGLIANO G, Shapiro GI, Kristeleit RS, Abdul Razak AR, et al
    Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
    Br J Cancer. 2023 Jan 25. doi: 10.1038/s41416-023-02161.
    PubMed    
    
    
    
80. EVANS DG, Phillips KA, Milne RL, Fruscio R, et al
    Correction to: Survival from breast cancer in women with a BRCA2 mutation by treatment.
    Br J Cancer. 2023 Jan 13. doi: 10.1038/s41416-022-02130.
    PubMed    
    
    
    December 2022
81. WU HL, Luo ZY, He ZL, Gong Y, et al
    All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits.
    Br J Cancer. 2022 Dec 23. doi: 10.1038/s41416-022-02111.
    PubMed     Abstract available
    
    
    
82. IBRAHIM SL, Abed MN, Mohamed G, Price JC, et al
    Inhibition of branched-chain alpha-keto acid dehydrogenase kinase augments the sensitivity of ovarian and breast cancer cells to paclitaxel.
    Br J Cancer. 2022 Dec 16. doi: 10.1038/s41416-022-02095.
    PubMed     Abstract available
    
    
    
83. ZHAO S, Pan T, Deng J, Cao L, et al
    Exosomal transfer of miR-181b-5p confers senescence-mediated doxorubicin resistance via modulating BCLAF1 in breast cancer.
    Br J Cancer. 2022 Dec 15. doi: 10.1038/s41416-022-02077.
    PubMed     Abstract available
    
    
    
84. YAZAKI S, Salgado R, Shimoi T, Yoshida M, et al
    Impact of adjuvant chemotherapy and radiotherapy on tumour-infiltrating lymphocytes and PD-L1 expression in metastatic breast cancer.
    Br J Cancer. 2022 Dec 15. doi: 10.1038/s41416-022-02072.
    PubMed     Abstract available
    
    
    
85. DIECI MV, Carbognin L, Miglietta F, Canino F, et al
    Correction: Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation.
    Br J Cancer. 2022 Dec 2. doi: 10.1038/s41416-022-02087.
    PubMed    
    
    
    
86. SHAABAN AM, Hilton B, Clements K, Dodwell D, et al
    The presentation, management and outcome of patients with ductal carcinoma in situ (DCIS) with microinvasion (invasion
    Br J Cancer. 2022;127:2125-2132.
    PubMed     Abstract available
    
    
    
87. SAHU R, Jha S, Pattanayak SP
    Therapeutic silencing of mTOR by systemically administered siRNA-loaded neutral liposomal nanoparticles inhibits DMBA-induced mammary carcinogenesis.
    Br J Cancer. 2022;127:2207-2219.
    PubMed     Abstract available
    
    
    November 2022
88. DIECI MV, Carbognin L, Miglietta F, Canino F, et al
    Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation.
    Br J Cancer. 2022 Nov 17. pii: 10.1038/s41416-022-02050.
    PubMed     Abstract available
    
    
    
89. GATHANI T, Dodwell D, Horgan K
    The impact of the first 2 years of the COVID-19 pandemic on breast cancer diagnoses: a population-based study in England.
    Br J Cancer. 2022 Nov 12. pii: 10.1038/s41416-022-02054.
    PubMed    
    
    
    
90. KOCK AM BRINK M, Dunst LS, Behrens HM, Kruger S, et al
    Intratumoral heterogeneity affects tumor regression and Ki67 proliferation index in perioperatively treated gastric carcinoma.
    Br J Cancer. 2022 Nov 8. pii: 10.1038/s41416-022-02047.
    PubMed     Abstract available
    
    
    
91. CURIGLIANO G, Shapiro GI, Kristeleit RS, Abdul Razak AR, et al
    A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
    Br J Cancer. 2022 Nov 5. pii: 10.1038/s41416-022-02025.
    PubMed     Abstract available
    
    
    
92. SHI Q, Xuhong J, Luo T, Ge J, et al
    PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer.
    Br J Cancer. 2022 Nov 2. pii: 10.1038/s41416-022-02021.
    PubMed     Abstract available
    
    
    
93. DELACOTE C, Delacour-Billon S, Ayrault-Piault S, Tagri AD, et al
    Is survival rate lower after breast cancer in deprived women according to disease stage?
    Br J Cancer. 2022 Nov 1. pii: 10.1038/s41416-022-02024.
    PubMed     Abstract available
    
    
    
94. SYRIOPOULOU E, Wasterlid T, Lambert PC, Andersson TM, et al
    Standardised survival probabilities: a useful and informative tool for reporting regression models for survival data.
    Br J Cancer. 2022;127:1808-1815.
    PubMed     Abstract available
    
    
    
95. MORRISSEY RL, Thompson AM, Lozano G
    Is loss of p53 a driver of ductal carcinoma in situ progression?
    Br J Cancer. 2022;127:1744-1754.
    PubMed     Abstract available
    
    
    
96. LUNDBERG P, Forsgren MF, Tellman J, Kihlberg J, et al
    Breast density is strongly associated with multiparametric magnetic resonance imaging biomarkers and pro-tumorigenic proteins in situ.
    Br J Cancer. 2022;127:2025-2033.
    PubMed     Abstract available
    
    
    October 2022
97. HUDSON BI, Lippman ME
    Comment on "The lingering mysteries of metastatic recurrence in breast cancer".
    Br J Cancer. 2022 Oct 31. pii: 10.1038/s41416-022-02012.
    PubMed    
    
    
    
98. TRAN TV, Rubino C, Allodji R, Andruccioli M, et al
    Breast cancer risk among thyroid cancer survivors and the role of I-131 treatment.
    Br J Cancer. 2022 Oct 12. pii: 10.1038/s41416-022-01982.
    PubMed     Abstract available
    
    
    
99. ZHANG M, Wang J, Jin Y, Zheng Q, et al
    YTHDF2-mediated FGF14-AS2 decay promotes osteolytic metastasis of breast cancer by enhancing RUNX2 mRNA translation.
    Br J Cancer. 2022 Oct 10. pii: 10.1038/s41416-022-02006.
    PubMed     Abstract available
    
    
    
100. JACOT W, Lusque A, Vicier C, Mailliez A, et al
     Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations.
     Br J Cancer. 2022 Oct 7. pii: 10.1038/s41416-022-02003.
     PubMed     Abstract available
     
     
     
101. FALLOWFIELD L, Solis-Trapala I, Starkings R, May S, et al
     Talking about Risk, UncertaintieS of Testing IN Genetics (TRUSTING): development and evaluation of an educational programme for healthcare professionals about BRCA1 & BRCA2 testing.
     Br J Cancer. 2022;127:1116-1122.
     PubMed     Abstract available
     
     
     
102. STANNARD R, Lambert PC, Andersson TM, Rutherford MJ, et al
     Obtaining long-term stage-specific relative survival estimates in the presence of incomplete historical stage information.
     Br J Cancer. 2022;127:1061-1068.
     PubMed     Abstract available
     
     
     
103. SLOTH RA, Axelsen TV, Espejo MS, Toft NJ, et al
     Loss of RPTPgamma primes breast tissue for acid extrusion, promotes malignant transformation and results in early tumour recurrence and shortened survival.
     Br J Cancer. 2022;127:1226-1238.
     PubMed     Abstract available
     
     
     September 2022
104. ALLEN I, Hassan H, Sofianopoulou E, Eccles D, et al
     Risk of developing a second primary cancer in male breast cancer survivors: a systematic review and meta-analysis.
     Br J Cancer. 2022 Sep 17. pii: 10.1038/s41416-022-01940.
     PubMed     Abstract available
     
     
     
105. FERNANDEZ-GARCIA D, Nteliopoulos G, Hastings RK, Rushton A, et al
     Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer.
     Br J Cancer. 2022 Sep 10. pii: 10.1038/s41416-022-01962.
     PubMed     Abstract available
     
     
     
106. ZAGOURI F, Koliou GA, Dimitrakopoulos F, Papadimitriou C, et al
     Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial.
     Br J Cancer. 2022;127:695-703.
     PubMed     Abstract available
     
     
     
107. LUO C, Zhao S, Peng C, Wang C, et al
     Mammography radiomics features at diagnosis and progression-free survival among patients with breast cancer.
     Br J Cancer. 2022 Sep 1. pii: 10.1038/s41416-022-01958.
     PubMed     Abstract available
     
     
     
108. NADER-MARTA G, Debien V, Eiger D, Tsourti Z, et al
     Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO study.
     Br J Cancer. 2022 Sep 1. pii: 10.1038/s41416-022-01963.
     PubMed     Abstract available
     
     
     August 2022
109. WOOF VG, Howell A, McWilliams L, Gareth Evans D, et al
     How do women who are informed that they are at increased risk of breast cancer appraise their risk? A systematic review of qualitative research.
     Br J Cancer. 2022 Aug 24. pii: 10.1038/s41416-022-01944.
     PubMed     Abstract available
     
     
     
110. INGEBRIKTSEN LM, Finne K, Akslen LA, Wik E, et al
     A novel age-related gene expression signature associates with proliferation and disease progression in breast cancer.
     Br J Cancer. 2022 Aug 23. pii: 10.1038/s41416-022-01953.
     PubMed     Abstract available
     
     
     
111. DEBIK J, Schafer H, Andreassen T, Wang F, et al
     Lipoprotein and metabolite associations to breast cancer risk in the HUNT2 study.
     Br J Cancer. 2022 Aug 4. pii: 10.1038/s41416-022-01924.
     PubMed     Abstract available
     
     
     July 2022
112. SHU X, Zhou Q, Sun X, Flesaker M, et al
     Associations between circulating proteins and risk of breast cancer by intrinsic subtypes: a Mendelian randomisation analysis.
     Br J Cancer. 2022 Jul 26. pii: 10.1038/s41416-022-01923.
     PubMed     Abstract available
     
     
     
113. VAN DEN BOSCH T, Rueda OM, Caldas C, Vermeulen L, et al
     Copy number heterogeneity identifies ER+ breast cancer patients that do not benefit from adjuvant endocrine therapy.
     Br J Cancer. 2022 Jul 21. pii: 10.1038/s41416-022-01906.
     PubMed     Abstract available
     
     
     
114. LI T, Houssami N, Noguchi N, Zeng A, et al
     Differential detection by breast density for digital breast tomosynthesis versus digital mammography population screening: a systematic review and meta-analysis.
     Br J Cancer. 2022;127:116-125.
     PubMed     Abstract available
     
     
     
115. ALLEN V, Coulombe J, Zhao H, Kreps LM, et al
     VIVA1: a more invasive subclone of MDA-MB-134VI invasive lobular carcinoma cells with increased metastatic potential in xenograft models.
     Br J Cancer. 2022;127:56-68.
     PubMed     Abstract available
     
     
     June 2022
116. ALMEKINDERS MM, Bismeijer T, Kumar T, Yang F, et al
     Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk.
     Br J Cancer. 2022 Jun 29. pii: 10.1038/s41416-022-01888.
     PubMed     Abstract available
     
     
     
117. LOFLING LL, Stoer NC, Sloan EK, Chang A, et al
     beta-blockers and breast cancer survival by molecular subtypes: a population-based cohort study and meta-analysis.
     Br J Cancer. 2022 Jun 20. pii: 10.1038/s41416-022-01891.
     PubMed     Abstract available
     
     
     
118. BRANTLEY KD, Zeleznik OA, Dickerman BA, Balasubramanian R, et al
     A metabolomic analysis of adiposity measures and pre- and postmenopausal breast cancer risk in the Nurses' Health Studies.
     Br J Cancer. 2022 Jun 18. pii: 10.1038/s41416-022-01873.
     PubMed     Abstract available
     
     
     
119. BARTLOME S, Berry CC
     Recent insights into the effects of metabolism on breast cancer cell dormancy.
     Br J Cancer. 2022 Jun 17. pii: 10.1038/s41416-022-01869.
     PubMed     Abstract available
     
     
     
120. BAKER JL, Di Meglio A, Gbenou AS, El Mouhebb M, et al
     Association between physical activity and neoadjuvant chemotherapy completion and pathologic complete response in primary breast cancer: the CANTO study.
     Br J Cancer. 2022 Jun 17. pii: 10.1038/s41416-022-01870.
     PubMed     Abstract available
     
     
     
121. SAURAV S, Manna SK
     Increased expression of Profilin potentiates chemotherapeutic agent-mediated tumour regression.
     Br J Cancer. 2022;126:1410-1420.
     PubMed     Abstract available
     
     
     May 2022
122. YAO X, He Z, Qin C, Zhang P, et al
     Inhibition of PFKFB3 in HER2-positive gastric cancer improves sensitivity to trastuzumab by inducing tumour vessel normalisation.
     Br J Cancer. 2022 May 30. pii: 10.1038/s41416-022-01834.
     PubMed     Abstract available
     
     
     
123. MICHMERHUIZEN AR, Lerner LM, Ward C, Pesch AM, et al
     Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer.
     Br J Cancer. 2022 May 26. pii: 10.1038/s41416-022-01849.
     PubMed     Abstract available
     
     
     
124. VALACHIS A, Carlqvist P, Ma Y, Szilcz M, et al
     Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study.
     Br J Cancer. 2022 May 21. pii: 10.1038/s41416-022-01845.
     PubMed     Abstract available
     
     
     
125. MIN HY, Lee HJ, Suh YA, Pei H, et al
     Targeting epidermal growth factor receptor in paclitaxel-resistant human breast and lung cancer cells with upregulated glucose-6-phosphate dehydrogenase.
     Br J Cancer. 2022 May 21. pii: 10.1038/s41416-022-01843.
     PubMed     Abstract available
     
     
     
126. GREENE G, Griffiths R, Han J, Akbari A, et al
     Impact of the SARS-CoV-2 pandemic on female breast, colorectal and non-small cell lung cancer incidence, stage and healthcare pathway to diagnosis during 2020 in Wales, UK, using a national cancer clinical record system.
     Br J Cancer. 2022 May 2. pii: 10.1038/s41416-022-01830.
     PubMed     Abstract available
     
     
     April 2022
127. JAMES AD, Leslie TK, Kaggie JD, Wiggins L, et al
     Sodium accumulation in breast cancer predicts malignancy and treatment response.
     Br J Cancer. 2022 Apr 25. pii: 10.1038/s41416-022-01802.
     PubMed     Abstract available
     
     
     
128. UMEH-GARCIA M, O'Geen H, Simion C, Gephart MH, et al
     Aberrant promoter methylation contributes to LRIG1 silencing in basal/triple-negative breast cancer.
     Br J Cancer. 2022 Apr 19. pii: 10.1038/s41416-022-01812.
     PubMed     Abstract available
     
     
     
129. CHAUHAN A, Pal A
     Comments on "Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer".
     Br J Cancer. 2022 Apr 12. pii: 10.1038/s41416-022-01804.
     PubMed    
     
     
     March 2022
130. GAHLAWAT AW, Fahed L, Witte T, Schott S, et al
     Total circulating microRNA level as an independent prognostic marker for risk stratification in breast cancer.
     Br J Cancer. 2022 Mar 22. pii: 10.1038/s41416-022-01756.
     PubMed     Abstract available
     
     
     
131. TOMICZEK-SZWIEC J, Szwiec M, Falco M, Cybulski C, et al
     The impact of oophorectomy on survival from breast cancer in patients with CHEK2 mutations.
     Br J Cancer. 2022 Mar 7. pii: 10.1038/s41416-022-01770.
     PubMed     Abstract available
     
     
     
132. CLIFT AK, Dodwell D, Lord S, Petrou S, et al
     The current status of risk-stratified breast screening.
     Br J Cancer. 2022;126:533-550.
     PubMed     Abstract available
     
     
     February 2022
133. DE GREGORIO A, Janni W, Friedl TWP, Nitz U, et al
     The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C.
     Br J Cancer. 2022 Feb 22. pii: 10.1038/s41416-021-01690.
     PubMed     Abstract available
     
     
     
134. MATIKAS A, Kotsakis A, Apostolaki S, Politaki H, et al
     Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer.
     Br J Cancer. 2022 Feb 10. pii: 10.1038/s41416-022-01699.
     PubMed     Abstract available
     
     
     
135. TUTZAUER J, Sjostrom M, Holmberg E, Karlsson P, et al
     Breast cancer hypoxia in relation to prognosis and benefit from radiotherapy after breast-conserving surgery in a large, randomised trial with long-term follow-up.
     Br J Cancer. 2022 Feb 9. pii: 10.1038/s41416-021-01630.
     PubMed     Abstract available
     
     
     
136. WEST CML
     Hypoxia does not predict lack of benefit from adjuvant radiotherapy for patients with early stage breast cancer.
     Br J Cancer. 2022 Feb 9. pii: 10.1038/s41416-022-01707.
     PubMed     Abstract available
     
     
     
137. DE BOO LW, Jozwiak K, Joensuu H, Lindman H, et al
     Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients.
     Br J Cancer. 2022 Feb 5. pii: 10.1038/s41416-022-01711.
     PubMed     Abstract available
     
     
     
138. DUFFY SW, Seedat F, Kearins O, Press M, et al
     The projected impact of the COVID-19 lockdown on breast cancer deaths in England due to the cessation of population screening: a national estimation.
     Br J Cancer. 2022 Feb 2. pii: 10.1038/s41416-022-01714.
     PubMed     Abstract available
     
     
     
139. BEDNARZ-KNOLL N, Popeda M, Kryczka T, Kozakiewicz B, et al
     Higher platelet counts correlate to tumour progression and can be induced by intratumoural stroma in non-metastatic breast carcinomas.
     Br J Cancer. 2022;126:464-471.
     PubMed     Abstract available
     
     
     January 2022
140. ZOU R, Loke SY, Tang YC, Too HP, et al
     Development and validation of a circulating microRNA panel for the early detection of breast cancer.
     Br J Cancer. 2022 Jan 10. pii: 10.1038/s41416-021-01593.
     PubMed     Abstract available
     
     
     
141. NAGHAVI-BEHZAD M, Vogsen M, Vester RM, Olsen MMB, et al
     Response monitoring in metastatic breast cancer: a comparison of survival times between FDG-PET/CT and CE-CT.
     Br J Cancer. 2022 Jan 10. pii: 10.1038/s41416-021-01654.
     PubMed     Abstract available
     
     
     December 2021
142. NYBERG T, Tischkowitz M, Antoniou AC
     BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis.
     Br J Cancer. 2021 Dec 28. pii: 10.1038/s41416-021-01675.
     PubMed     Abstract available
     
     
     
143. ADIB E, El Zarif T, Nassar AH, Akl EW, et al
     CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer.
     Br J Cancer. 2021 Dec 23. pii: 10.1038/s41416-021-01673.
     PubMed     Abstract available
     
     
     
144. VEITCH Z, Ribnikar D, Tilley D, Tang PA, et al
     No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer.
     Br J Cancer. 2021 Dec 20. pii: 10.1038/s41416-021-01676.
     PubMed     Abstract available
     
     
     
145. HARVIE M, Pegington M, Howell SJ, Bundred N, et al
     Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer.
     Br J Cancer. 2021 Dec 15. pii: 10.1038/s41416-021-01650.
     PubMed     Abstract available
     
     
     
146. HANNA K, Krzoska E, Shaaban AM, Muirhead D, et al
     Raman spectroscopy: current applications in breast cancer diagnosis, challenges and future prospects.
     Br J Cancer. 2021 Dec 10. pii: 10.1038/s41416-021-01659.
     PubMed     Abstract available
     
     
     November 2021
147. CANELO-AYBAR C, Posso M, Montero N, Sola I, et al
     Benefits and harms of annual, biennial, or triennial breast cancer mammography screening for women at average risk of breast cancer: a systematic review for the European Commission Initiative on Breast Cancer (ECIBC).
     Br J Cancer. 2021 Nov 26. pii: 10.1038/s41416-021-01521.
     PubMed     Abstract available
     
     
     
148. JAGGUPILLI A, Ly S, Nguyen K, Anand V, et al
     Metabolic stress induces GD2(+) cancer stem cell-like phenotype in triple-negative breast cancer.
     Br J Cancer. 2021 Nov 22. pii: 10.1038/s41416-021-01636.
     PubMed     Abstract available
     
     
     
149. SCOTT NP, Teoh EJ, Flight H, Jones BE, et al
     Characterising (18)F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging.
     Br J Cancer. 2021 Nov 18. pii: 10.1038/s41416-021-01623.
     PubMed     Abstract available
     
     
     
150. BYUN D, Hong S, Ryu S, Nam Y, et al
     Early-life body mass index and risks of breast, endometrial, and ovarian cancers: a dose-response meta-analysis of prospective studies.
     Br J Cancer. 2021 Nov 12. pii: 10.1038/s41416-021-01625.
     PubMed     Abstract available
     
     
     
151. SUPPAN C, Graf R, Jahn S, Zhou Q, et al
     Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients.
     Br J Cancer. 2021 Nov 9. pii: 10.1038/s41416-021-01601.
     PubMed     Abstract available
     
     
     
152. ROMUALDO CARDOSO S, Gillespie A, Haider S, Fletcher O, et al
     Functional annotation of breast cancer risk loci: current progress and future directions.
     Br J Cancer. 2021 Nov 5. pii: 10.1038/s41416-021-01612.
     PubMed     Abstract available
     
     
     
153. PARKES EE, Savage KI, Lioe T, Boyd C, et al
     Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer.
     Br J Cancer. 2021 Nov 2. pii: 10.1038/s41416-021-01599.
     PubMed     Abstract available
     
     
     
154. VAN SEIJEN M, Lips EH, Fu L, Giardiello D, et al
     Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast.
     Br J Cancer. 2021;125:1443-1449.
     PubMed     Abstract available
     
     
     October 2021
155. HU J, Lai Y, Huang H, Ramakrishnan S, et al
     TCOF1 upregulation in triple-negative breast cancer promotes stemness and tumour growth and correlates with poor prognosis.
     Br J Cancer. 2021 Oct 30. pii: 10.1038/s41416-021-01596.
     PubMed     Abstract available
     
     
     
156. GUZMAN-AROCHO YD, Rosenberg SM, Garber JE, Vardeh H, et al
     Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer.
     Br J Cancer. 2021 Oct 26. pii: 10.1038/s41416-021-01597.
     PubMed     Abstract available
     
     
     
157. BLACKFORD AL, Childs EJ, Porter N, Petersen GM, et al
     A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO.
     Br J Cancer. 2021 Oct 26. pii: 10.1038/s41416-021-01580.
     PubMed     Abstract available
     
     
     
158. KNUTSEN E, Harris AL, Perander M
     Expression and functions of long non-coding RNA NEAT1 and isoforms in breast cancer.
     Br J Cancer. 2021 Oct 20. pii: 10.1038/s41416-021-01588.
     PubMed     Abstract available
     
     
     
159. SI S, Li J, Tewara MA, Li H, et al
     Identifying causality, genetic correlation, priority and pathways of large-scale complex exposures of breast and ovarian cancers.
     Br J Cancer. 2021 Oct 20. pii: 10.1038/s41416-021-01576.
     PubMed     Abstract available
     
     
     
160. HERZOG SK, Fuqua SAW
     ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges.
     Br J Cancer. 2021 Oct 7. pii: 10.1038/s41416-021-01564.
     PubMed     Abstract available
     
     
     September 2021
161. BIZOT A, Karimi M, Rassy E, Heudel PE, et al
     Multicenter evaluation of breast cancer patients' satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic.
     Br J Cancer. 2021 Sep 29. pii: 10.1038/s41416-021-01555.
     PubMed     Abstract available
     
     
     
162. WANG C, Hu K, Luo C, Deng L, et al
     Cardiovascular mortality among cancer survivors who developed breast cancer as a second primary malignancy.
     Br J Cancer. 2021 Sep 27. pii: 10.1038/s41416-021-01549.
     PubMed     Abstract available
     
     
     
163. GWILI N, Jones SJ, Amri WA, Carr IM, et al
     Transcriptome profiles of stem-like cells from primary breast cancers allow identification of ITGA7 as a predictive marker of chemotherapy response.
     Br J Cancer. 2021;125:983-993.
     PubMed     Abstract available
     
     
     
164. LIU Z, Thong MSY, Doege D, Koch-Gallenkamp L, et al
     Prevalence of benefit finding and posttraumatic growth in long-term cancer survivors: results from a multi-regional population-based survey in Germany.
     Br J Cancer. 2021;125:877-883.
     PubMed     Abstract available
     
     
     
165. BURNSIDE ES, Warren LM, Myles J, Wilkinson LS, et al
     Quantitative breast density analysis to predict interval and node-positive cancers in pursuit of improved screening protocols: a case-control study.
     Br J Cancer. 2021;125:884-892.
     PubMed     Abstract available
     
     
     August 2021
166. AMIRI SOURI E, Chenoweth A, Cheung A, Karagiannis SN, et al
     Cancer Grade Model: a multi-gene machine learning-based risk classification for improving prognosis in breast cancer.
     Br J Cancer. 2021;125:748-758.
     PubMed     Abstract available
     
     
     July 2021
167. JOSEPH R, Soundararajan R, Vasaikar S, Yang F, et al
     CD8(+) T cells inhibit metastasis and CXCL4 regulates its function.
     Br J Cancer. 2021;125:176-189.
     PubMed     Abstract available
     
     
     June 2021
168. CHEN F, Han Y, Kang Y
     Bone marrow niches in the regulation of bone metastasis.
     Br J Cancer. 2021;124:1912-1920.
     PubMed     Abstract available
     
     
     May 2021
169. AMADOU A, Freisling H, Jenab M, Tsilidis KK, et al
     Prevalent diabetes and risk of total, colorectal, prostate and breast cancers in an ageing population: meta-analysis of individual participant data from cohorts of the CHANCES consortium.
     Br J Cancer. 2021;124:1882-1890.
     PubMed     Abstract available
     
     
     
170. BARTSCH R, Singer CF, Pfeiler G, Hubalek M, et al
     Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34.
     Br J Cancer. 2021;124:1795-1802.
     PubMed     Abstract available
     
     
     March 2021
171. ARTHUR RS, Dannenberg AJ, Kim M, Rohan TE, et al
     The association of body fat composition with risk of breast, endometrial, ovarian and colorectal cancers among normal weight participants in the UK Biobank.
     Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-020-01210.
     PubMed     Abstract available
     
     
     
172. PAI BELLARE G, Saha B, Patro BS
     Targeting autophagy reverses de novo resistance in homologous recombination repair proficient breast cancers to PARP inhibition.
     Br J Cancer. 2021;124:1260-1274.
     PubMed     Abstract available
     
     
     
173. BADVE SS, Cho S, Gokmen-Polar Y, Sui Y, et al
     Multi-protein spatial signatures in ductal carcinoma in situ (DCIS) of breast.
     Br J Cancer. 2021;124:1150-1159.
     PubMed     Abstract available
     
     
     
174. WINKLER C, Armenia J, Jones GN, Tobalina L, et al
     SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.
     Br J Cancer. 2021;124:951-962.
     PubMed     Abstract available
     
     
     
175. ZENG Y, Gao W, Chen X, Shen K, et al
     Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component.
     Br J Cancer. 2021;124:975-981.
     PubMed     Abstract available
     
     
     
176. SHAABAN AM, Hilton B, Clements K, Provenzano E, et al
     Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project.
     Br J Cancer. 2021;124:1009-1017.
     PubMed     Abstract available
     
     
     February 2021
177. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
     Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
     Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.